Donate

In the News

Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.

Recent news

Dislaying 1 — 6 of 360
  • Show Your Stripes Saturday for Rare Disease Day 

    Affected by a rare disease? Show your stripes on Rare Disease Day, Saturday, Feb. 28, to support rare and complex conditions that affect one in 10 Americans. Together, they are 25 million strong. Whether you’ll be rocking zebra-print outfits, painting your face or baking striped cookies, join PHA on social media Saturday and share how you show your stripes, using the hashtags #PHAssociation, #ShowYourStripes and #RareDiseaseDay.

    Living with PH

  • CEO Update: Seeking New Possibilities in a New Year CEO Update Matt
    CEO Update: Celebrating 35 Years of PHA Awareness

    As the Pulmonary Hypertension Association turns 35, we have much to celebrate. In the past three decades, PHA has achieved many wins in fulfilling our mission. As we continue our work to improve and extend the lives of people affected by PH, we’re looking forward to PHA 2026 International PH Conference, Rare Disease Day on Feb. 28 and our March 9 advocacy event on Capitol Hill.

  • PHA 2024 Attendees Show How They’re ‘Stronger Together’ PHA2024_Wrapup_wide
    PHixin’ to Join Us? Register for PHA 2026 starting March 2 

    Registration opens Monday, March 2, for PHA 2026 International PH Conference and Scientific Sessions. Make sure your PHA membership is up to date to receive discounted member rates and apply for scholarships to further reduce conference costs.

    Education | Events

  • Who Are PHA’s Outstanding Members? Meet 8 Dedicated Volunteers PHA2024_OutstandingMembers_wide
    Recognize an Outstanding PHA Member  

    Do you know someone who goes above and beyond for their service to the pulmonary hypertension community? Nominate them for our Outstanding Member Awards. Nominations open March 2 and close April 13. The awards recognize volunteer efforts in patient and caregiver support, advocacy, promoting quality patient care and advancing research. PHA will present the awards at PHA 2026 International PH Conference and Scientific Sessions, June 11-14 in Dallas.

    Events

  • Advocating for Oxygen Access on Capitol Hill 

    Maurita Andrews lives in Washington state with her husband and their two sons. Diagnosed with pulmonary arterial hypertension in 2019, Andrews has dedicated her time to raising PH awareness.

    Get involved | Living with PH

  • Help Your Support Group Win a Lunch Party 

    The Pulmonary Hypertension Association’s created a new Member Get a Member campaign for support groups — and your group could win a fun celebratory party. Contacting your support group leader to receive campaign materials and learn how to participate. Then encourage members of your support group, family and friends to join the PHA community as members by May 1. Members who recruit new members will have a chance to win PHA swag and a $100 Amazon gift card.

    Support

PH in the News

Ralinepag shows delayed disease progression in PAH study

Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.

Read more

Pulmovant completes Phase 2 study enrollment for PH-ILD drug

Pulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.

Read more

Gossamer announces topline results from Phase 3 seralutinib study

Gossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).

Read more
Industry news

Back to Top